Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Salicylamide: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Salicylamide: Detailed Review of its Transformative R&D Success
20 September 2023
This article summarized the latest R&D progress of Salicylamide, the Mechanism of Action for Salicylamide, and the drug target R&D trends for Salicylamide.
Read →
Progress in the Research of COMT Inhibitors
Progress in the Research of COMT Inhibitors
20 September 2023
Catechol O-methyltransferase (COMT) is an enzyme responsible for the O-methylation of endogenous neurotransmitters, xenobiotics, and hormones with catechol structures.
Read →
Decoding Vilobelimab: A Comprehensive Study of its R&D Trends
Drug Insights
4 min read
Decoding Vilobelimab: A Comprehensive Study of its R&D Trends
19 September 2023
This article summarized the latest R&D progress of Vilobelimab, the Mechanism of Action for Vilobelimab, and the drug target R&D trends for Vilobelimab.
Read →
InnoCare Reveals approval of the Clinical Experiment for ICP-189, Coupled with EGFR Inhibitor Furmonertinib
Latest Hotspot
3 min read
InnoCare Reveals approval of the Clinical Experiment for ICP-189, Coupled with EGFR Inhibitor Furmonertinib
19 September 2023
InnoCare Pharma announced that it received IND approval for a Chinese clinical trial to study the effects of new SHP2 allosteric inhibitor, ICP-189.
Read →
 Deep Scientific Insights on Vandetanib's R&D Progress
Drug Insights
4 min read
Deep Scientific Insights on Vandetanib's R&D Progress
19 September 2023
This article summarized the latest R&D progress of Vandetanib, the Mechanism of Action for Vandetanib, and the drug target R&D trends for Vandetanib.
Read →
Strategy for Retrieving Bispecific Antibody Sequences
Bio Sequence
2 min read
Strategy for Retrieving Bispecific Antibody Sequences
19 September 2023
Using the Patsnap Bio Sequence Database for bispecific antibody sequence retrieval is recommended.
Read →
An In-depth Analysis of Thioguanine's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
4 min read
An In-depth Analysis of Thioguanine's R&D Progress and Mechanism of Action on Drug Target
19 September 2023
This article summarized the latest R&D progress of Thioguanine, the Mechanism of Action for Thioguanine, and the drug target R&D trends for Thioguanine.
Read →
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
Latest Hotspot
3 min read
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
19 September 2023
Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.
Read →
 Stavudine: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Stavudine: Detailed Review of its Transformative R&D Success
19 September 2023
This article summarized the latest R&D progress of Stavudine, the Mechanism of Action for Stavudine, and the drug target R&D trends for Stavudine.
Read →
"Super drugs" for treating cancer and AIDS: Chemokines family
Advanced Tech.
10 min read
"Super drugs" for treating cancer and AIDS: Chemokines family
19 September 2023
Chemokines, also known as chemotactic cytokines, are a group of factors that, in conjunction with their cell surface receptors, induce the directed migration of leukocytes.
Read →
Quinidine Gluconate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Quinidine Gluconate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Quinidine Gluconate, the Mechanism of Action for Quinidine Gluconate, and the drug target R&D trends for Quinidine Gluconate.
Read →
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
Latest Hotspot
4 min read
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
19 September 2023
NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.
Read →